Eric is our Vice President of Development and Operations. He has a strong multidisciplinary background in metabolic disease and oncology targets with over 25 years of experience in the biotech/pharmaceutical industry. Prior to joining Metacrine, Eric served as senior director of operations and contracts at Seragon Pharmaceuticals. At Seragon he was involved in business development efforts resulting in the acquisition of Seragon by Genentech. Prior to Seragon, Eric served as director of operations at Aragon Pharmaceuticals and as a pharmacologist at X-Ceptor Therapeutics, Ligand Pharmaceuticals and Hybritech, Inc. He received his B.S. in biology from the University of California, San Diego.
Nicholas is our Senior Vice President of Chemistry with more than 20 years of drug discovery experience in the pharmaceutical industry. Most recently at Seragon Pharmaceuticals and Aragon Pharmaceuticals, he was Vice President of Chemistry where he oversaw medicinal chemistry projects, including the development of two estrogen receptor degrader clinical candidates, and a next-generation androgen receptor antagonist program. In addition, Nicholas was responsible for the Aragon and then Seragon intellectual property portfolios and aspects of clinical manufacturing. Prior to Aragon, he was Head of Chemistry at Kalypsys Pharmaceuticals. Prior to Kalypsys, Nicholas was a Research Fellow at Merck & Co., where he led chemistry groups that contributed to clinical candidates in the areas of obesity and inflammation. Nicholas was a post-doctoral fellow at the University of Toronto and has a Ph.D. in synthetic organic chemistry from the University of Southampton, UK.
Hubert is our Chief Medical Officer, with ~15 years of experience in the biotech industry. Prior to joining Metacrine, he was Chief Medical and Scientific Officer at Pfenex Inc., overseeing research and development and leading regulatory interactions with US FDA, EMA, Japan’s PMDA and Health Canada. Before that, Hubert held increasingly senior positions at Aileron Therapeutics, Regulus Therapeutics, and Amylin Pharmaceuticals, responsible for translational medicine and clinical development in metabolic disorders, inflammation/fibrosis, hepatitis C and oncology. Prior to starting his biotech career at Amgen, Hubert was Staff Research Investigator at the Gladstone Institute of Cardiovascular Disease, conducting basic research in diabetes and lipid metabolism. Hubert trained in Endocrinology at the University of California, San Francisco and Internal Medicine at the Massachusetts General Hospital. He received his M.D. from Columbia University and B.A.S. in political sciences and biology from Stanford University.
Trisha is our Chief Financial Officer. She has a strong background in healthcare finance and business operations that stretches back more than 15 years, across multiple companies. Most recently she served as the Senior Vice President of Finance at Seragon Pharmaceuticals, a private biotechnology company focused on developing selective estrogen receptor degraders targeting hormone dependent cancers, which was acquired by Genentech. Before that she was Vice President of Finance at Aragon Pharmaceuticals, a discovery-stage small molecule company focused on therapeutics for the treatment of hormone resistant cancers, which was acquired by Johnson and Johnson. Previously, she worked in various senior financial management roles at Zogenix, a pharmaceutical company developing and commercializing innovative central nervous system therapies. Trisha spent five years with the public accounting firm Deloitte. She holds a B.S. in accounting from the University of San Diego and is a certified public accountant in the state of California.
Ken is our President and Chief Executive Officer and a member of our board of directors. He has more than 10 years’ experience developing and building companies in the life sciences and the diagnostic industry. Prior to joining Metacrine, he was the Chief Executive Officer of Ariosa Diagnostics, Inc., a DNA molecular diagnostics company. Before that he was a Vice President at Venrock, a venture capital firm, leading investments in private and public healthcare companies. Previously, Ken trained as both an internist and gastroenterologist and conducted translational and clinical outcome research at the University of California, San Francisco, University of Washington and the Fred Hutchinson Cancer Center. He started his business career as a consultant at McKinsey. Ken also serves as Executive Chairman of Omniome, a DNA sequencing company. He holds a B.S. in biology from the Massachusetts Institute of Technology and an M.D. from the University of California, San Francisco.